Quince Therapeutics
QNCX
79 hedge funds and large institutions have $827M invested in Quince Therapeutics in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 27 reducing their positions, and 10 closing their positions.
16% more capital invested
Capital invested by funds: $715M → $827M (+$112M)
6% more call options, than puts
Call options by funds: $473K | Put options by funds: $445K
0.02% more ownership
Funds ownership: 0.26% → 0.28% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 27
2% less funds holding
Funds holding: 81 → 79 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$35.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.48M |
| 3 |
ECG
EPIQ Capital Group
San Francisco,
California
|
+$3.27M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.23M |
| 5 |
PHAM
Pacific Heights Asset Management
San Francisco,
California
|
+$2.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.57M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.92M |
| 3 |
Millennium Management
New York
|
-$1.17M |
| 4 |
Renaissance Technologies
New York
|
-$1.03M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$782K |
QNCX Hedge Fund Activity: Q3 2020 in Review
79 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q3 2020, worth a combined $827M — up 16% from $715M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of QNCX and 8 opened new positions — a net loss of 2 holders — while 27 trimmed existing stakes and 26 added.
The largest buyer was Capital International Investors, adding an estimated $35.3M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $3.57M sold.
- 79 institutional investors held Quince Therapeutics (QNCX) as of Q3 2020, down from 81 in Q2 2020.
- Funds reported $827M of Quince Therapeutics stock for Q3 2020, up 16% quarter-over-quarter.
- 8 funds opened new Quince Therapeutics positions in Q3 2020 and 10 closed out, a net change of -2 holders.
- The largest Quince Therapeutics buyer in Q3 2020 was Capital International Investors, an estimated $35.3M added.
- The largest Quince Therapeutics seller in Q3 2020 was T. Rowe Price Associates, an estimated $3.57M sold.
Based on aggregated 13F filings for Q3 2020.